$LFCR

Lifecore Biomedical (LFCR) reported Q2 2026 revenue of $34.2M, down 6.2% year over year, and a net loss of $6.2M ($0.19/share). Adjusted EBITDA was $8.6M. Gross margin fell to 35.3%. The company reaffirmed 2026 revenue guidance of $120M to $125M and adjusted EBITDA guidance of $20.5M to $25M, citing a 2027 demand inflection tied to Japanese market approval.

Lifecore Biomedical (NASDAQ: LFCR) reported Q2 2026 revenues of $34.2M, down 6.2% year over year, and net loss of $6.2M ($0.19 per diluted share). Six-month revenues fell to $57.4M. Gross profit declined, while liquidity was about $38.8M. The company signed six new programs in Q2, added 13 over 12 months, and reaffirmed 2026 guidance.

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lfcr-2026q2xex991earningsr.htm EX-99.1 Document Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026 , and Provides Corporate Update -- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs t

Lifecore Biomedical (NASDAQ: LFCR) said it signed three new customer agreements. One covers late-stage regenerative medicine technology transfer, engineering support, GMP readiness and PPQ services. Two are early-stage deals, including formulation optimization for a global medical technology company. Lifecore expects the programs to contribute to 2028 revenue.

Laughing Water Capital’s Q2 2026 investor letter says its portfolio gained about 39.8% in Q2 and 33.6% YTD. It highlights Lifecore Biomedical, Inc. (NASDAQ:LFCR), a contract drug manufacturing firm, noting LFCR closed at $4.61 on July 14, 2026 and has fallen 39.97% over 52 weeks. The letter cites LFCR’s post-quarter 8-K about Series A Preferred redemptions and evaluating strategic alternatives.

Lifecore Biomedical (NASDAQ: LFCR) said it signed a new agreement with a global pharmaceutical company to provide technical transfer services supporting commercial manufacturing of an injectable suspension product for neurological disorders. The company said it is the seventh late-stage program agreement in seven months, adding to its CDMO pipeline.

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 a2026stockincentiveplan.htm EX-10.1 Document Exhibit 10.1 LIFECORE BIOMEDICAL, INC. 2026 STOCK INCENTIVE PLAN SECTION 1. INTRODUCTION. 1.1 The Lifecore Biomedical, Inc. 2026 Stock Incentive Plan (the “Plan”) will be effective on October 16, 2026 (the “Effective Date”),

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Lifecore Biomedical, Inc. (LFCR) and certain officers/directors for alleged corporate wrongdoing. The firm encourages investors who purchased Lifecore securities before October 7, 2020, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and seeks to recover investor capital and ensure corporate accountability.

Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of Ibotta, Inc., Lifecore Biomedical, Inc., Molina Healthcare, Inc., and WEBTOON Entertainment Inc. The law office is encouraging long-term shareholders of these companies, who purchased shares during specific periods, to contact them to seek corporate reforms and other remedies at no cost. The investigations stem from alleged misleading statements, internal control deficiencies, and other issues that affected the companies' financial projections and investor information.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Lifecore Biomedical, Inc. (NASDAQ: LFCR), Molina Healthcare, Inc. (NYSE: MOH), and WEBTOON Entertainment, Inc. (NASDAQ: WBTN). These investigations concern alleged breaches of fiduciary duties by officers and directors, ranging from misleading statements and delayed disclosures to deficient internal controls and misrepresentations of performance metrics. Shareholders who held shares prior to specific dates are encouraged to contact Grabar Law Office to seek corporate reforms and other remedies.